Indication intelligence, analysis and sector perception

Bellicum Pharmaceuticals (BLCM), appointed Alan K. Smith, PhD as SVP of Manufacturing.

October 29, 2015 9:45am

Dr. Smith joins with over 30 years of experience in cellular therapeutics, during which time he served in various leadership roles in Research and Development, Manufacturing and Quality.

Most recently, he was Vice President of Research & Development and Cellular Therapeutics at LifeNet Health, an organ procurement organization and tissue bank, and its wholly owned subsidiary, The Institute of Regenerative Medicine, a global research center focused on innovations in cellular therapies and tissue engineering.

Previously, Dr. Smith served as a consultant to the cell therapy industry, contributing to over 25 successful FDA regulatory submissions for cell therapy products and devices. He also served as President and Chief Executive Officer of Cognate BioServices, Inc., a contract service provider performing R&D and contract manufacturing for clients developing cellular therapies in regenerative medicine for cancer, immunotherapy, cardiovascular and neurological applications. Previously, he was the Chief Operating Officer and Senior Vice President of Research & Development at Osiris Therapeutics, where he created clinical processes and systems to deliver cell and gene therapies for hematopoietic, cardiovascular, immunotherapy and orthopedic applications.

Earlier in his career, Dr. Smith led R&D functions for Aastrom Biosciences, Inc. (now Vericel Corporation), Geneic Sciences, Inc. and Baxter Healthcare Corporation, Immunotherapy Division.

Dr. Smith is an Adjunct Professor in the Department of Biology and Molecular Cell Biology at Eastern Virginia Medical School and has previously held adjunct professorships at California State University Long Beach and Utah State University. Dr. Smith earned his Bachelor of Science in Chemistry at Southern Utah State College and his doctorate in Biochemistry at Utah State University.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

3 hours 34 min ago
RegMed Investors (RMi) Closing Bell: this week’s trend is an admission that the sector is without pricing sustainability suppressing a value directional

12 hours 35 min ago
RegMed Investors’ (RMi) pre-open: the down draft doesn’t seem to be over

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.